- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00812227
Neural Correlates of Psychodynamic Psychotherapy for Depression
9 de maio de 2013 atualizado por: Joshua L. Roffman MD, MMSc, Massachusetts General Hospital
The purpose of this study is to see whether we can predict which patients with depression will get better when we treat them with psychodynamic psychotherapy.
We will use neuroimaging (a method of looking at brain activity) in this study.
We want to see whether there are changes in the brains of patients receiving this type of therapy.
We hypothesize that these changes may predict how well certain parts of the psychotherapy treatment process works.
Visão geral do estudo
Status
Concluído
Condições
Intervenção / Tratamento
Descrição detalhada
In this study, we will treat patients with brief psychodynamic psychotherapy.
Psychodynamic psychotherapy is a type of treatment that may be as helpful as medications in treating depression.
It focuses on thoughts, feelings, and behaviors as well as both current and past relationships.
Psychotherapy explores better ways of coping with feelings, expressing needs, and interacting with others in order to cope with depression and other life problems.
Subjects will go to 16 weekly, 45-minute, individual sessions of psychodynamic psychotherapy over the course of the study.
At five times throughout the study, subjects will come in for extra visits, which last approximately 1.5 hours and which include: speaking with a study doctor about depressive symptoms, filling out extra questionnaires, and performing positron emission tomography (PET)and a Quantitative Electroencephalogram (QEEG).
The QEEG is a machine that measures the electrical activity of the brain.
This task will take approximately 15 minutes.
Tipo de estudo
Intervencional
Inscrição (Real)
35
Estágio
- Não aplicável
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Locais de estudo
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02114
- Depression Clinical and Research Program
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
18 anos a 60 anos (Adulto)
Aceita Voluntários Saudáveis
Não
Gêneros Elegíveis para o Estudo
Tudo
Descrição
Inclusion Criteria:
- Subjects will be adults, ages 18 to 60 years;
- Able to provide written informed consent;
- MDD, current according to the fourth version of the Diagnostic and Statistical Manual for Mental Disorders (DSM-IV);
- QIDS-SR score of >= 12 at screen;
- Current major depressive episode (MDE) length of < 5 year;
- Treated with an SSRI, SNRI, or bupropion at adequate doses (defined as 20 mg/day or more of fluoxetine, citalopram, or paroxetine; 10 mg/day or more of escitalopram; 50 mg/day or more of sertraline; 75 mg/day or more of venlafaxine; 15 mg/day of mirtazapine; or 40 mg/day of duloxetine; or 100mg/day of bupropion(wellbutrin)) during the current episode for at least 8 weeks; and,
- At the time of screen visit, patients must be on a stable dose of SSRI, SNRI, or bupropion for the past 4 weeks.
Exclusion Criteria:
- Pregnant women or women of child bearing potential who are not using a medically accepted means of contraception (to include oral contraceptive or implant, condom, diaphragm, spermicide, intrauterine device, tubal ligation, or a partner with vasectomy). Women of childbearing age who wish to enter the study will be required to undergo a pregnancy test (beta-HCG) prior to initiating treatment; an additional blood pregnancy test (beta HCG) will be completed if subject wants to do PET scan
- Patients who, in the investigator's judgment, pose a current, serious suicidal or homicidal risk. These patients will be immediately referred to appropriate clinical treatment;
- Patients who, in the opinion of the therapist, are not depressed at the time of their first psychotherapy visit;
- Patients who are currently being treated by a psychotherapist individually or who have received individual psychotherapy during the past 6 months. Couples therapy and family therapy will not be considered exclusionary criteria;
- Patients with neurological illnesses, including a history of seizure or head trauma with loss of consciousness;
- Patients with unstable diabetes, kidney disease, or significant medical illness;
- Patients with history of allergy to FDG
- The following DSM-IV diagnoses: substance use disorders active within the last six months, any bipolar disorder (current or past), any psychotic disorder (current or past), any post-traumatic stress disorder (current or past), any obsessive compulsive disorder (current or past), or any panic disorder (current, past allowed). Generalized anxiety disorder or adjustment disorder are not exclusionary;
- Patients currently requiring other psychotropic medications, including anticonvulsants, benzodiazepines, antipsychotics, stimulants, or sedative hypnotics (other than diphenhydramine);however, patients will be permitted to take trazodone in addition to their primary antidepressant if it is taken as a sleep aid, rather than a primary antidepressant;
- Psychotic features in the current episode, or a history of psychotic features, as assessed by SCID;
- Patients who have undergone > 3 previous adequate attempts at psychodynamic psychotherapy (deemed "adequate" by the screening physician), which were considered unhelpful or unsuccessful by patient report (according to patient report);
- Patients with a history of antidepressant-induced hypomania; and
- Patients with a history of medication non-compliance.
- Patients with Axis II pathology (personality disorder) that, in the opinion of the screening physician, would interfere with subjects' ability to participate in the treatment and/or comply with the protocol, such as severe borderline or narcissistic personality disorder.
- Patients who have had electroconvulsive therapy (ECT) within the 12 months preceding baseline
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Psychodynamic psychotherapy
|
Screened and eligible patients will receive 16 individual sessions of psychodynamic psychotherapy, each lasting 45-50 minutes.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
---|---|
Correlation between changes in HAMD-17 and changes in QEEG measurements (theta cordance) from treatment initiation to two weeks after starting treatment
Prazo: Weeks 0 through 16
|
Weeks 0 through 16
|
PET: Treatment-related change in FDG metabolism within regions-of-interest identified at baseline as related to depression severity.
Prazo: Week 0, Week 16
|
Week 0, Week 16
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Joshua Roffman, MD, Massachusetts General Hospital Department of Psychiatry
- Investigador principal: Janet Witte, MD, MPH, Massachusetts General Hospital Department of Psychiatry
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo
1 de agosto de 2008
Conclusão Primária (Real)
1 de fevereiro de 2013
Conclusão do estudo (Real)
1 de fevereiro de 2013
Datas de inscrição no estudo
Enviado pela primeira vez
18 de dezembro de 2008
Enviado pela primeira vez que atendeu aos critérios de CQ
19 de dezembro de 2008
Primeira postagem (Estimativa)
22 de dezembro de 2008
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
13 de maio de 2013
Última atualização enviada que atendeu aos critérios de controle de qualidade
9 de maio de 2013
Última verificação
1 de maio de 2013
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 2008-P-001181
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Transtorno Depressivo Maior
-
Centre Hospitalier Universitaire de Saint EtienneBayerRescindido
-
Memorial Sloan Kettering Cancer CenterAtivo, não recrutandoDiagnóstico confirmado de ß-talassemia MajorEstados Unidos
-
Assiut UniversityAinda não está recrutando
-
Università degli Studi di FerraraConcluído
-
HaEmek Medical Center, IsraelConcluído
-
Cerus CorporationConcluído
-
National Taiwan University HospitalRecrutamentoTalassemia MajorTaiwan
-
DisperSol Technologies, LLCConcluídoTalassemia MajorTailândia, Estados Unidos
-
Assiut UniversityConcluído
-
National Human Genome Research Institute (NHGRI)ConcluídoTalassemia MajorCingapura
Ensaios clínicos em Psychodynamic Psychotherapy
-
Yale UniversityNational Institute of Mental Health (NIMH)ConcluídoEstresse de minoria sexualEstados Unidos